Clin Neurophysiol: New sensitive electroencephalogram measurements can be used for functional connections for Alzheimer's disease.

In clinical trials of Alzheimer's disease (AD), improvements in impaired functional connectivity (FC) can provide biological support for the drug's potential efficacy.
the EEG analysis of the SAPHIR trial, the treatment improved the overall relative theta power, but could not measure FC by phase lag index (PLI).
we compared the Amplitude Envelope correlation between the PLI and the leak correction (AEC-c), which may be a more sensitive FC measurement. Early ad-
patients were treated with a placebo or glutamate reaminase inhibitor PQ912 for 12 weeks.
measured closed-eye, untasked EEG at baseline and follow-up (PQ912 n s 47, placebo n s 56).
measure AEC-c and PLI in multiple frequency bands.
compare strain of FC between treatment groups by using two covariate models.
results showed a significant increase in the global AEC-c treatment of PQ912 in the alpha band compared to placebo (p s 0.004, Cohen's d s 0.58).
the effect is still significant when the gender, country, ApoE s4 carry, age, baseline value (model 1; p , 0.006) and relative alpha power changes (model 2; p s 0.004).
, the results show that after PQ912 treatment, the functional connectivity of Early AD scants using AEC-c in the alpha band has improved.
.